Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Plus Therapeutics Stock: A Rapid Surge or Short-Lived Bounce?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 3/21/2025, 9:19 am ET 6 min read
Plus Therapeutics Stock: A Rapid Surge or Short-Lived Bounce? Thumbnail

In this article

  • PSTV-4.27%
    PSTV - NASDAQPLUS THERAPEUTICS Inc.
    $0.32-0.01 (-4.27%)
    Volume:  507818
    Float:  16.36M
    $0.31Day Low/High$0.38

Amid significant market pressure, PLUS THERAPEUTICS Inc.’s stocks are influenced by concerns over financing challenges and broader market stresses, as reflected in Friday’s trading down by -15.94 percent.

Recent Buzz Taking the Market by Storm:

  • The stock for Plus Therapeutics, identified by the symbol PSTV, has seen a sudden spike of nearly 150% in recent trading sessions, sparking keen interest and speculation within the financial community.

Candlestick Chart

Live Update At 09:18:35 EST: On Friday, March 21, 2025 PLUS THERAPEUTICS Inc. stock [NASDAQ: PSTV] is trending down by -15.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • An influx of investor activity is linked to the ongoing developments in cancer drug trials, as speculated from recent announcements and the rich pipeline of oncology therapeutics growing under PSTV’s wing.

  • There’s an undercurrent of optimism in the market as the company continues cultivating strategic partnerships and collaborations with major players in the pharmaceutical industry.

  • Plus Therapeutics has made bold claims on future profitability driven by their proprietary nanoparticle technology, fueling the surging excitement around its stock.

  • Investor sentiment is swaying, with forums and social media abuzz as traders and shareholders dissect recent PR, hoping to capitalize on next big pharma wave crest.

Financial Pulse Check

As a trader, it’s crucial to understand that success in the stock market doesn’t happen overnight. There are inevitable challenges and setbacks along the way. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” By adopting this mindset, traders can learn from their experiences, refine their tactics, and grow more resilient over time. This approach not only helps in managing the emotional rollercoaster associated with trading but also nurtures a strategic perspective towards achieving long-term trading goals.

The latest financial reports are painting a mixed picture. The revenue figures hover around $4.9M, revealing a valuation measure of 0.34 in price-to-sales ratio, indicating that the market values the company’s stock less than its revenues. This suggests a conservative investor outlook but also underlines potential value for those buying into Plus Therapeutics early.

An evident fact from reviewing the financials is the significant negative margin, with both pre-tax profit margin and net profit margin diving deep into the negatives at -418.8% and -146.11% respectively. These figures symbolize underlying risk tied to the company’s financial health. However, the inflated gross margin of 85.9% provides a beacon of hope, summoning those who might trust in PSTV’s future income shifts.

More Breaking News

Financially, the asset turnover stands at 0.9, hinting the company manages its assets efficiently, driving more revenue per unit of asset owned, albeit sinking returns on assets and equity pose a sensationalized mirror of potential downfall if unmitigated.

Market Sentiments:

The marketplace has latched onto the recent news of promising drug trial advancements, seeing it as a harbinger for significant changes in Plus Therapeutics’ prospects within the biotechnology landscape. Traders now face the classic showdown: patience vs. action. While some hail this rally as the window to profit, urging peers to get aboard, others tread with caution, wary of volatility.

Beyond The Buzzword: What Could Follow?

Plus Therapeutics’ quest for innovation, particularly its nanoparticle delivery system, positions it ahead in the arena of cancer therapies. But, amidst this buzz of hope looms the challenge of translating research to market-ready products without financially imploding.

Intrinsic financials alone don’t justify the hype, with the current ratio showing liquidity concerns at a feeble 0.4, indicating a potential strain on meeting obligations. However, in the realm of speculative trading, the focus often bypasses mundane figures, cartwheeling towards ‘what might be’. It’s a double-edged sword; prospects of astounding growth tempered by devastating falls for those who misjudge their seat in the trend.

Final Thoughts:

As the dust settles and the next trading session dawns, aficionados of PSTV must wade through the emotions barley reaching through the cacophony of sound financial judgment. While the allure of high rewards beckons, sticking firmly to disciplined hard-facts analysis and understanding underlying risks could lead investors through the thick fog of market volatility.

Only Time Will Tell:

The clash between emerging potential and stern reality dominates our current stock narrative. It’s a story still unfolding, one where lessons are scribed as stark reminders to the eager as well as the wise – a waiting game for Plus Therapeutics to truly justify its spot in the limelight. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This piece of wisdom reminds traders to be patient, learn from setbacks, and continuously refine their trading approach as they navigate the turbulent stock market waters.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

In this article (YTD Performance)

  • PSTV-73.12%
    PSTV - NASDAQPLUS THERAPEUTICS Inc.
    $0.32-0.01 (-4.27%)
    Volume:  507818
    Float:  16.36M
    $0.31Day Low/High$0.38

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications